• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同期放化疗治疗 III 期非小细胞肺癌的有前途的治疗方案:使用数学分析替代常规分割。

The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.

机构信息

Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Anticancer Res. 2020 Jul;40(7):4095-4104. doi: 10.21873/anticanres.14408.

DOI:10.21873/anticanres.14408
PMID:32620658
Abstract

BACKGROUND/AIM: To evaluate treatment schedules involving concurrent chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) using the tumor control probability (TCP) and normal tissue complication probability (NTCP) parameters.

PATIENTS AND METHODS

The standard schedules were compared with two types of schedules, the dose escalation and the short-term schedules. Standard schedules were 60-74 Gy in 30-37 fractions. The dose escalation schedules with hypofractionation and hyperfractionation were 69 Gy in 30 fractions and 69.6 Gy in 58 fractions, respectively, twice per day (b.i.d). The short-term schedules were concomitant boost, 64 Gy in 40 fractions b.i.d. and the accelerated radiotherapy schedule, 57.6 Gy in 36 fractions, three fractions per day (t.i.d).

RESULTS

The average TCP for the short-term schedules was more than 16% in two tumor models; however, the TCP for standard and dose escalation schedules was less than 5%. In each organ, the increase in NTCP for the short-term schedule compared with standard schedules was less than 15%.

CONCLUSION

The short-term schedules had an advantage over standard schedules for NSCLC.

摘要

背景/目的:利用肿瘤控制概率(TCP)和正常组织并发症概率(NTCP)参数,评估 III 期非小细胞肺癌(NSCLC)中同步放化疗的治疗方案。

患者和方法

将标准方案与两种方案进行比较,即剂量递增和短期方案。标准方案为 30-37 次分割 60-74Gy。每日两次的低分割和超分割剂量递增方案分别为 69Gy/30 次和 69.6Gy/58 次。短期方案为同期加量,64Gy/40 次,每日两次,64Gy/40 次;加速放疗方案为 57.6Gy/36 次,每日三次。

结果

两种肿瘤模型中,短期方案的平均 TCP 均超过 16%;然而,标准和剂量递增方案的 TCP 均低于 5%。在每个器官中,与标准方案相比,短期方案的 NTCP 增加均低于 15%。

结论

对于 NSCLC,短期方案优于标准方案。

相似文献

1
The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.同期放化疗治疗 III 期非小细胞肺癌的有前途的治疗方案:使用数学分析替代常规分割。
Anticancer Res. 2020 Jul;40(7):4095-4104. doi: 10.21873/anticanres.14408.
2
Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.加速、剂量递增、序贯放化疗治疗非小细胞肺癌(ADSCaN):一项随机Ⅱ期研究方案。
BMJ Open. 2019 Jan 29;9(1):e019903. doi: 10.1136/bmjopen-2017-019903.
3
A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.一项采用累及野适形放疗和加速超分割进行放化疗的 III 期非小细胞肺癌的 I 期研究:WJTOG 3305。
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):327-31. doi: 10.1016/j.ijrobp.2011.06.1991. Epub 2011 Nov 11.
4
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.标准剂量与高剂量适形放疗联合并巩固使用卡铂加紫杉醇,联合或不联合西妥昔单抗治疗IIIA期或IIIB期非小细胞肺癌患者(RTOG 0617):一项随机、二乘二析因3期研究。
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
5
Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.同步化疗中进行中等剂量放疗剂量递增对Ⅲ期非小细胞肺癌有益吗?一项多机构倾向评分匹配分析。
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033.
6
Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.同期加量调强放疗或调强质子放疗联合同步化疗治疗Ⅱ期至Ⅲ期非小细胞肺癌:Ⅰ期研究。
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):730-737. doi: 10.1016/j.ijrobp.2017.10.042. Epub 2017 Nov 3.
7
Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report.同步放化疗联合累及野适形放疗和加速超分割放疗并结合顺铂和长春瑞滨化疗治疗Ⅲ期非小细胞肺癌的剂量递增研究:最终报告
Am J Clin Oncol. 2018 Oct;41(10):967-971. doi: 10.1097/COC.0000000000000412.
8
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.一项I期研究,旨在确定在标准每日放疗和超分割加速每日两次放疗方案联合化疗治疗局限期小细胞肺癌时的最大耐受辐射剂量。
J Clin Oncol. 1998 Nov;16(11):3528-36. doi: 10.1200/JCO.1998.16.11.3528.
9
High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.采用同步加量的高剂量、超分割、加速放疗治疗非小细胞肺癌:异常毒性及有前景的早期结果
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):593-9. doi: 10.1016/s0360-3016(96)00353-7.
10
Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial.根据正常组织剂量限制制定非小细胞肺癌的放射剂量处方:一项计算机模拟临床试验。
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1103-10. doi: 10.1016/j.ijrobp.2007.11.028. Epub 2008 Feb 6.